scholarly journals 1129 UK Based Experience of The Elipsetm Intragastric Balloon; Short Term Safety and Effectiveness

2021 ◽  
Vol 108 (Supplement_6) ◽  
Author(s):  
A Sandhya ◽  
B Oyewole ◽  
I Stefanova ◽  
S Mangat ◽  
S Monkhouse
Keyword(s):  
Weight Loss ◽  
Average Weight ◽  
Gastric Balloon ◽  
Short Term ◽  
X Ray ◽  
Sustained Weight Loss ◽  
Lost To Follow Up

Abstract Aim Intra Gastric Balloons (IGB) have been used over the last three decades as a minimally invasive, non-surgical weight-loss option. The ElipseTM gastric balloon (EIGB) is a ‘procedure-less’ gastric balloon which can be placed in an average of 20 minutes without the need of endoscopy or sedation. The aim of our study is to investigate the first cohort of patients in uk who underwent IGB capsule and short term follow up. Method Single centre retrospective study of the first consecutive 202 patients that had the Eclipse IGB inserted between May 2018 and November 2020. Patients swallow the ElipseTM capsule and pre-inflation x-ray is taken to confirm correct positioning after which the gastric balloon is inflated with 550mls of sterile water and a post-inflation x-ray is taken. The balloon is designed to be in-situ for 4 months and then automatically deflates. Results Out of 202 patients 24 were lost to follow-up, 146 patients followed up to an average of 15 weeks, while 26 patients followed up to 4 weeks. Average weight loss at 4 weeks was 6% Total Weight Loss (%TWL) while at last follow up 9.63% TWL. Majority of patients experienced post procedural reflux, abdominal pain, bloating and vomiting. 6 patients had early removal of the balloon due to severe symptoms (4), pancreatitis (1) and hyperinflation (1). 1 had early expulsion at 2 months. Conclusions Eclipse IGB is safe and effective in selective patients, however long-term follow is needed to compare it with the other balloons in terms of significant and sustained weight loss.

Zeolite - Salt Occlusion: A Potential Route for the Immobilisation of Iodine-129?

2003 ◽  
Vol 807 ◽  
Author(s):  
Neil C. Hyatt ◽  
Joseph A. Hriljac ◽  
Alia Choudhry ◽  
Laura Malpass ◽  
Gareth P. Sheppard ◽  
...  
Keyword(s):  
Weight Loss ◽  
Uniform Distribution ◽  
Crystalline Phase ◽  
Thermally Stable ◽  
X Ray Diffraction ◽  
Single Crystalline ◽  
X Ray ◽  
Elemental Silver

ABSTRACTReactions of zeolite Na-A with AgI, and the sodium, copper and lead forms of zeolites A, LTA, X and Y with NaI, have been examined as possible starting routes to the long term immobilisation of iodine-129. Heating the salts in air, at 500°C, with the sodium forms of the zeolites leads to the formation of occlusion products, where the iodide salt migrates into the zeolite pores. Detailed studies of the Na-A / 5AgI complex indicate it has a uniform distribution of Na, Si, Al, Ag and I, and is thermally stable to ca. 750°C, where there is a substantial weight loss as iodine is released. In situ powder X-ray diffraction studies have been used to monitor the occlusion reaction at 400°C, and show that the occlusion product decomposes to produce a single crystalline phase at 800°C prior to further decomposition at 850°C to a mixture of nepheline and elemental silver.

scholarly journals Weight and Glycemic Control Outcomes of Bariatric Surgery and Pharmacotherapy in Patients With Melanocortin-4 Receptor Deficiency

2022 ◽  
Vol 12 ◽  
Author(s):  
Esphie Grace Fodra Fojas ◽  
Saradalekshmi Koramannil Radha ◽  
Tomader Ali ◽  
Evan P. Nadler ◽  
Nader Lessan
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Glycemic Control ◽  
Therapeutic Interventions ◽  
Control Group ◽  
Short Term ◽  
Melanocortin 4 Receptor ◽  
Significant Difference

BackgroundMelanocortin-4 receptor (MC4R) mutations are the most common of the rare monogenic forms of obesity. However, the efficacy of bariatric surgery (BS) and pharmacotherapy on weight and glycemic control in individuals with MC4R deficiency (MC4R-d) is not well-established. We investigated and compared the outcomes of BS and pharmacotherapy in patients with and without MC4R-d.MethodsPertinent details were derived from the electronic database among identified patients who had BS with MC4R-d (study group, SG) and wild-type controls (age- and sex-matched control group, CG). Short- and long-term outcomes were reported for the SG. Short-term outcomes were compared between the two groups.ResultsSeventy patients were screened for MC4R-d. The SG [six individuals (four females, two males); 18 (10–27) years old at BS; 50.3 (41.8–61.9) kg/m2 at BS, three patients with homozygous T162I mutations, two patients with heterozygous T162I mutations, and one patient with heterozygous I170V mutation] had a follow-up duration of up to 10 years. Weight loss, which varied depending on mutation type [17.99 (6.10–22.54) %] was stable for 6 months; heterogeneity of results was observed thereafter. BS was found superior to liraglutide on weight and glycemic control outcomes. At a median follow-up of 6 months, no significant difference was observed on weight loss (20.8% vs. 23.0%, p = 0.65) between the SG and the CG [eight individuals (four females, four males); 19.0 (17.8–36.8) years old at BS, 46.2 (42.0–48.3) kg/m2 at BS or phamacotherapeutic intervention]. Glycemic control in patients with MC4R-d and Type 2 diabetes improved post-BS.ConclusionOur data indicate efficacious short-term but varied long-term weight loss and glycemic control outcomes of BS on patients with MC4R-d, suggesting the importance of ongoing monitoring and complementary therapeutic interventions.

scholarly journals The Effects of If-Then Plans on Weight Loss: Results of the 24-Month Follow-up of the McGill CHIP Healthy Weight Program Randomized Controlled Trial

2019 ◽  
Author(s):  
Barbel Knauper ◽  
huma shireen ◽  
Kimberly Carriere ◽  
Mallory Frayn ◽  
Elena Ivanova ◽  
...  
Keyword(s):  
Weight Loss ◽  
Controlled Trial ◽  
Diabetes Prevention Program ◽  
Weight Loss Maintenance ◽  
Study Data ◽  
Average Weight ◽  
Healthy Weight ◽  
Clinically Significant

Abstract Background: The NIH-developed Diabetes Prevention Program (DPP) is successful in achieving clinically significant weight loss in individuals with overweight/obesity when delivered one-on-one. However, due to high cost of implementation, the long-term effectiveness remains limited. In response, a group-based version of the program, called the National DPP, was developed. The average weight loss following participation in this program was only about 3.5% with low long-term weight loss maintenance. Purpose: We aimed to optimize weight loss outcomes of the National DPP by integrating the habit formation tool of if-then plans into the program. Results at 3 and 12 months of participation showed no between-group differences between standard and enhanced DPP but higher weight loss in both groups compared to the National DPP. This paper reports the long-term weight loss maintenance data following participation in the program. Methods: Of the 172 participants enrolled at the beginning of the study, data from 110 participants was available and analyzed at 24 months, i.e. 12 months following the end of the 12-month intervention. Results: No between-group difference in weight loss maintenance was seen. Pooled results showed a significant weight regain from 12 to 24 months, i.e. an average of 7.85lbs of the 20.36lbs lost. However, participants from both groups were still 12.51lbs or 6.13% lighter at 24 months than at baseline. Conclusion: If-then plans did not result in a higher percentage of weight loss at 24-month follow-up. However, at 24 months, both groups maintained a significant portion of the weight lost at the end of intervention.

Characteristics of elderly metastatic prostate cancer (M1 PC) long-term survivors in the SEER Medicare database receiving androgen-deprivation therapy (ADT)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e17513-e17513
Author(s):  
N. A. Obeidat ◽  
C. D. Mullins ◽  
E. Onukwugha ◽  
B. Seal ◽  
A. Hussain
Keyword(s):  
Clinical Characteristics ◽  
Population Based ◽  
Short Term ◽  
Time To First Treatment ◽  
Medicare Database ◽  
Different Characteristics ◽  
Lost To Follow Up ◽  
Long Term Survivors

e17513 Background: ADT remains standard treatment for pts with M1 PC, with radiation (RT) and chemotherapy (CT) providing additional palliation. This population-based analysis evaluated if long-term survivors (LT) receiving ADT possessed different characteristics relative to short-term survivors (ST). Methods: Pts age >/= 66y in SEER Medicare diagnosed with M1 PC between 1998 and 2002 and receiving ADT with or without subsequent CT were identified. Median overall survival (OS) for the sample was used as a cut-off to categorize ST and LT pts. Within these categories, demographic, and clinical characteristics were evaluated. Results: 2,665 ADT pts were first identified who had median OS of 26 months (95% CI 24.0 - 27.0). 1,349 pts died at </= 26 months (ST pts), while 1,245 pts survived or were lost to follow-up beyond 26 months (LT pts). Median time to first treatment with ADT was 1 mo in both ST and LT groups. Within this 66y+ population, LT pts were younger (p < 0.0001), more likely to be married (p = 0.0277), and were comprised of lower % of non-Hispanic white pts and higher % of ‘other’ races, but comparable % of African American and White-Hispanics (p = 0.0005). Distributional differences in PSA were detected, but interpreting the results was difficult due to missing or unknown information. Both ST and LT pts received RT and prostatectomy at similar rates, but LT pts had less comorbidities (p = 0.0008), and were more likely to receive CT (p = 0.0026). Conclusions: Long-term survivors were found to have demographic and clinical characteristics that differed from short-term survivors. Evidence regarding how these characteristics simultaneously impact the type and timing of treatment as well as survival deserve more exploration. [Table: see text]

scholarly journals Revisional One Anastomosis Gastric Bypass with a 150-cm Biliopancreatic Limb After Failure of Adjustable Gastric Banding: Mid-Term Outcomes and Comparison Between One- and Two-Stage Approaches

2021 ◽  
Author(s):  
Niccolò Petrucciani ◽  
Francesco Martini ◽  
Marine Benois ◽  
Radwan Kassir ◽  
Hubert Boudrie ◽  
...  
Keyword(s):  
Weight Loss ◽  
Gastric Bypass ◽  
Gastric Banding ◽  
Adjustable Gastric Banding ◽  
Postoperative Morbidity ◽  
Biliopancreatic Limb ◽  
The Mean ◽  
Lost To Follow Up

Abstract Purpose Laparoscopic adjustable gastric banding (LAGB) was a common procedure worldwide but associated with a high rate of long-term failure. This study aims to evaluate the safety and effectiveness of conversion to one anastomosis gastric bypass (OAGB) after failed LAGB. Materials and Methods We undertook a retrospective analysis of a prospectively maintained database in a tertiary referral center for bariatric surgery. All cases of revisional OAGB with a biliopancreatic limb (BPL) of 150 cm after failed LAGB performed between 2010 and 2016 were analyzed. Results Overall, 215 patients underwent conversion from LAGB to OAGB. Indication for surgery was primary weight loss (WL) failure in 30.7% of cases and long-term complications in the remaining patients, with or without associated weight regain. At the time of OAGB, the mean age was 43.2 ± 10.5 years and the mean BMI was 42 ± 6.9. Overall postoperative morbidity was 13.5%. The postoperative abscess ± leak rate was 5.9% in the overall population. Two years after OAGB, 9.7% of patients were lost to follow-up, % excess weight loss (EWL) was 88.2 ± 23.9, and % total weight loss (TWL) was 38.7 ± 9.3. At 5 years, 16.6% of patients were lost to follow-up, %EWL was 82.4 ± 25, and %TWL was 36.1 ± 10. There was no statistical difference in complication rates or WL results between the one-stage and two-stage approaches. Conclusion OAGB with a 150-cm BPL represents a safe and effective option after failed LAGB. Both synchronous OAGB and two-step revisional OAGB guarantee satisfying results in terms of postoperative morbidity and WL outcomes. Graphical abstract (PLEASE CORRECT THE GRAPHICAL ABSTRACT !!! 215 PATIENTS INSTEAD OF 250

scholarly journals The effects of if-then plans on weight loss: results of the 24-month follow-up of the McGill CHIP Healthy Weight Program randomized controlled trial

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Bärbel Knäuper ◽  
◽  
Huma Shireen ◽  
Kimberly Carrière ◽  
Mallory Frayn ◽  
...  
Keyword(s):  
Physical Activity ◽  
Weight Loss ◽  
Controlled Trial ◽  
Weight Loss Maintenance ◽  
Current Evidence ◽  
Health Improvement ◽  
Average Weight ◽  
Healthy Weight

Abstract Background Current evidence suggests that some of the most effective weight loss approaches are changes in dietary and physical activity behaviors through lifestyle modification programs. The Group Lifestyle Balance (GLB) program is a group-based behavior modification program aimed at changing diet and physical activity for weight loss. It was developed to be more cost-effective and easier to disseminate than its individually administered parent program, the Diabetes Prevention Program (DPP). However, the average weight loss following participation in the GLB is only approximately 3.5%, with low long-term weight loss maintenance. Purpose We aimed to optimize the weight loss outcomes of the GLB to increase the efficacy already afforded by its cost-effectiveness and ease of dissemination. We did this by integrating the habit formation tool of if-then plans into the program. This program is called the enriched GLB or the McGill Comprehensive Health Improvement (CHIP) Healthy Weight Program. Results at 3 and 12 months of participation have already been published elsewhere. They showed no between-group differences between the standard and enriched GLB but higher weight loss in both groups compared to the DPP. This paper reports the long-term weight loss maintenance data following participation in the program. Methods Of the 172 participants enrolled at the beginning of the study, data from 110 participants were available and analyzed at 24 months, i.e., 12 months after the end of the 12-month intervention. Results No between-group difference in weight loss maintenance was observed. Pooled results showed a significant weight regain from 12 to 24 months, i.e., an average of 7.85 lbs. of the 20.36 lbs. lost. However, participants from both groups were still 12.51lbs or 6.13% lighter at 24 months than at baseline. Conclusion If-then plans did not result in a higher percentage of weight loss at 24-month follow-up compared to the standard GLB. However, at 24 months, both groups did show a maintenance of a significant portion of the weight lost at the end of intervention. Trial registration ClinicalTrials.gov Identifier: NCT02008435, registered 6 December 2013.

scholarly journals Eighteen Years Experience of Granulocyte Donations - Acceptable Donor Safety?

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5819-5819
Author(s):  
Ulla Axdorph Nygell ◽  
Agneta Sollén-Nilsson ◽  
Magnus Bjorkholm ◽  
Joachim Lundahl
Keyword(s):  
Conflicts Of Interest ◽  
Biliary Cirrhosis ◽  
Short Term ◽  
Life Threatening ◽  
Short And Long Term ◽  
Deceased Donors ◽  
Design And Methods

Abstract Background. Granulocyte transfusions are given to patients with life-threatening infections, refractory to treatment. The donors are stimulated with corticosteroids +/- G-CSF. However, data regarding the donor’s safety is sparse. The objective was therefore to evaluate short and long term adverse events (AE) in stimulated donors. Study design and methods. All consecutive granulocyte donors 1994-2012 were identified through our registry. Data were evaluated for the number of aphereses, stimulation therapy, AE, blood values post donation and recent status from the donation records. Results. 154 volunteer donors were mobilized for 359 collections. Age at first granulocyte donation was 43 years (median; range 19-64 years). Follow-up was 60 months (median; range 0-229 months). The dose G-CSF per collection was 3.8 ug/kg body weight (median; range 1.6-6.0 ug/kg). Sedimentation agent was HES. Short term AE were mild. Blood values 4 weeks post donation with minor reductions/elevations mostly resolved in later donations. Fourteen donors were excluded from the registry due to hypertension (4), diabetes (2), atrial fladder (1), ca mammae (1), ca in situ urethra (1), MGUS (1), thrombosis (1), anaphylaxis (1), primary biliary cirrhosis (1), unknown (1). Three donors are deceased due to diabetes, acute myocardial infarction and unknown cause. Time from first donation to exclusion was 37 months (median; range 1-198). All donors except one were excluded/died at least 6 months after the first granulocyte donation. Conclusion. No serious short term AE were observed. Due to the variability of diagnoses among excluded /deceased donors, we propose that it is less likely that granulocyte donations have a causative impact on these donors’ exclusion or death. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document